Head of MM-MRD Diagnostics
University Hospital Würzburg, Germany
Paula Tabares, PhD
Senior Scientist
Interdisciplinary Center for Clinical Research Laboratory
Department of Medicine II, University Hospital of Würzburg, Germany
• Doctoral degree in natural sciences (2011). University of Würzburg, Germany.
• From 2012 to 2017, researcher at the group of Prof. Dr. Thomas Hünig at the University of Würzburg, where she studied the effects of the CD28 superagonist TGN1412 on regulatory T-cells and contributed to the return of TGN1412 therapy to clinical development for the treatment of rheumatoid arthritis.
• In 2018, she joined the research group of Prof. Andreas Beilhack, at the University Hospital of Würzburg where she implemented the diagnostic platform to evaluate minimal residual disease (MRD) by NGF (Euroflow) in multiple myeloma (MM) patients in Würzburg, which is one of the leading myeloma centers in Germany, under the direction of Prof. Hermann Einsele, a key opinion leader in the myeloma field.
• Additionally to her role as the head of the MM-MRD diagnostic platform, Dr. Tabares is involved in different research areas in myeloma. For example and of great interest, she is conducting studies to further evaluate the role of junction adhesion molecules expressed on malignant circulating plasma cells and their prognostic impact in myeloma patients.
• Dr. Tabares also participates in different collaborations with industry partners, and European research initiatives such as the Horizon project “ELMUMMY” focused on the elucidation of risk factors and health determinants associated with progression of Monoclonal Gammopathies to Multiple Myeloma.